MG-K10
Phase 2Small molecule
MG-K10 is one of 71 small molecule programs targeting Atopic Dermatitis. It is currently in Phase 2.
3
Indications
6
Total Trials
3
Active Trials
70
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1050 competitors in Asthma
#DrugCompanyPhaseTrials
1Veramyst
GSKPreclinical
Singulair
AstraZenecaPreclinical
Cinqair
TevaPreclinical
Dupixent
AAzienda U.S.L. 1 di Massa e Carrara
Preclinical
Celexa
AbbViePreclinical
MG-K10
SShanghai Mabgeek Biotech.Co.Ltd
Phase 2
Aciphex
Akero TherapeuticsPreclinical
Atrovent
Boehringer IngelheimPreclinical
Decadron
QQuince Therapeutics S.p.A.
Preclinical
Aclidinium Bromide
AstraZenecaPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Atopic Dermatitis2 trials
Seasonal Allergic Rhinitis1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for MG-K10. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- SShanghai Mabgeek Biotech.Co.Ltd